HRP20161520T1 - Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju - Google Patents

Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju Download PDF

Info

Publication number
HRP20161520T1
HRP20161520T1 HRP20161520TT HRP20161520T HRP20161520T1 HR P20161520 T1 HRP20161520 T1 HR P20161520T1 HR P20161520T T HRP20161520T T HR P20161520TT HR P20161520 T HRP20161520 T HR P20161520T HR P20161520 T1 HRP20161520 T1 HR P20161520T1
Authority
HR
Croatia
Prior art keywords
sialylation
alpha
recombinant fsh
rfsh
cell line
Prior art date
Application number
HRP20161520TT
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161520(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP20161520T1 publication Critical patent/HRP20161520T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

1. Rekombinantni FSH (rFSH) uključujući α2,3- i a2,6-sialilaciju naznačen time da je 80% ili više od ukupne sialilacije α2,3-sialilacija i pri čemu od 5% do 20% od ukupne sialilacije je α2,6-sialilacija.
2. Rekombinantni FSH prema zahtjevu 1 naznačen time da je eksprimiran u ljudskoj staničnoj liniji.
3. Farmaceutski pripravak naznačen time da sadrži rFSH prema zahtjevu 1 ili zahtjevu 2.
4. Farmaceutski pripravak prema zahtjevu 3 naznačen time da dodatno sadrži hCG i/ili LH.
5. Farmaceutski pripravak prema zahtjevu 3 ili 4 naznačen time da je za uporabu za liječenje neplodnosti.
6. Postupak proizvodnje rFSH prema bilo kojem od zahtjeva 1 ili 2 naznačen time da sadrži korak proizvodnje ili eksprimiranja rFSH u ljudskoj staničnoj liniji.
7. Postupak prema zahtjevu 6 naznačen time da je stanična linija izmijenjena upotrebom α2,3-sialiltransferaze i/ili α2,6-sialiltransferaze.
HRP20161520TT 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju HRP20161520T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
HRP20161520T1 true HRP20161520T1 (hr) 2016-12-30

Family

ID=39717519

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2014-06-09 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju
HRP20161520TT HRP20161520T1 (hr) 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2014-06-09 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Country Status (29)

Country Link
US (5) US8951967B2 (hr)
EP (7) EP3098234A1 (hr)
JP (7) JP2011519359A (hr)
KR (5) KR20160056960A (hr)
CN (3) CN105906703A (hr)
AR (1) AR071479A1 (hr)
AU (5) AU2009237479B2 (hr)
BR (1) BRPI0910461B8 (hr)
CA (1) CA2725257A1 (hr)
CY (1) CY1115413T1 (hr)
DK (4) DK2808340T3 (hr)
ES (3) ES2468318T3 (hr)
FR (1) FR17C1020I2 (hr)
HK (2) HK1146284A1 (hr)
HR (3) HRP20140535T1 (hr)
HU (5) HUE033830T2 (hr)
IL (2) IL208538A (hr)
LT (4) LT2808340T (hr)
MX (3) MX2010011343A (hr)
NO (2) NO2017025I1 (hr)
NZ (1) NZ588381A (hr)
PL (4) PL2268666T3 (hr)
PT (4) PT3144318T (hr)
RU (3) RU2682270C2 (hr)
SA (1) SA109300228B1 (hr)
SI (4) SI2808340T1 (hr)
TW (1) TWI488640B (hr)
WO (1) WO2009127826A1 (hr)
ZA (1) ZA201007373B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2848687B1 (en) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Novel expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
JP7079094B2 (ja) 2015-04-17 2022-06-01 フェリング ベスローテン フェンノートシャップ 不妊症の処置のための組成物
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
ES2904787T3 (es) 2017-09-01 2022-04-06 Ferring Bv Composición para la estimulación ovárica controlada
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
KR20210079276A (ko) 2018-10-17 2021-06-29 훼링 비.브이. 제어된 난소 자극을 위한 조성물 및 방법
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
WO1998031826A1 (en) 1997-01-16 1998-07-23 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
ATE332705T1 (de) 1999-05-07 2006-08-15 Applied Research Systems Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
RS32804A (en) * 2001-10-22 2007-02-05 Applied Research Systems Ars Holding N.V., Gonadotrophins for folliculogenesis
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
BR112016023668A2 (pt) 2014-04-18 2017-10-17 Glycotope Gmbh hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Also Published As

Publication number Publication date
BRPI0910461B1 (pt) 2021-02-23
TW200948378A (en) 2009-12-01
JP6762916B2 (ja) 2020-09-30
LTPA2017018I1 (lt) 2017-06-26
LT3045471T (lt) 2017-07-10
CN102066414A (zh) 2011-05-18
IL230571A (en) 2015-11-30
RU2014141994A3 (hr) 2018-05-28
DK2808340T3 (en) 2016-12-05
EP2268666A1 (en) 2011-01-05
HRP20140535T1 (hr) 2014-07-18
US9771407B2 (en) 2017-09-26
RU2745557C3 (ru) 2021-12-10
JP2022031652A (ja) 2022-02-22
DK3144318T3 (da) 2020-12-07
US10995128B2 (en) 2021-05-04
PT3144318T (pt) 2020-11-04
US20180079794A1 (en) 2018-03-22
WO2009127826A1 (en) 2009-10-22
KR20180095140A (ko) 2018-08-24
PT3045471T (pt) 2017-06-14
EP3045471B1 (en) 2017-03-29
KR101622944B1 (ko) 2016-05-23
JP2011519359A (ja) 2011-07-07
EP4015527A1 (en) 2022-06-22
AU2014203277C1 (en) 2017-07-27
AU2017204258A1 (en) 2017-07-20
JP2015120696A (ja) 2015-07-02
RU2682270C2 (ru) 2019-03-18
ES2468318T3 (es) 2014-06-16
MX355457B (es) 2018-04-19
HK1199039A1 (en) 2015-06-19
JP2020040956A (ja) 2020-03-19
RU2010141908A (ru) 2012-05-27
JP2024038000A (ja) 2024-03-19
US20110105398A1 (en) 2011-05-05
CN105906702A (zh) 2016-08-31
PL3144318T3 (pl) 2021-02-08
AU2017204259A1 (en) 2017-07-20
US20210332099A1 (en) 2021-10-28
EP2268666B1 (en) 2014-03-12
AU2014203277A1 (en) 2014-07-24
KR102108377B1 (ko) 2020-05-08
PL3045471T3 (pl) 2017-10-31
EP2722339A1 (en) 2014-04-23
US20150065695A1 (en) 2015-03-05
BRPI0910461A2 (pt) 2018-03-27
ZA201007373B (en) 2011-06-29
HUE030652T2 (en) 2017-05-29
AR071479A1 (es) 2010-06-23
DK3045471T3 (en) 2017-06-26
SI2808340T1 (sl) 2016-12-30
US11952407B2 (en) 2024-04-09
RU2745557C1 (ru) 2021-03-29
FR17C1020I1 (hr) 2020-04-10
HUE033830T2 (en) 2018-01-29
RU2014141994A (ru) 2016-05-10
AU2009237479B2 (en) 2014-05-15
JP2018021037A (ja) 2018-02-08
EP3098234A1 (en) 2016-11-30
NO2017050I1 (no) 2017-09-28
JP7316905B2 (ja) 2023-07-28
CN105906703A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
ES2610277T3 (es) 2017-04-26
HUS1700036I1 (hu) 2017-10-30
SI3144318T1 (sl) 2020-12-31
JP6486310B2 (ja) 2019-03-20
DK2268666T3 (da) 2014-05-12
KR20160056960A (ko) 2016-05-20
EP3144318A1 (en) 2017-03-22
PL2268666T3 (pl) 2014-08-29
KR20110005863A (ko) 2011-01-19
EP2808340A1 (en) 2014-12-03
SA109300228B1 (ar) 2014-04-08
RU2537268C2 (ru) 2014-12-27
LT2808340T (lt) 2016-11-10
NZ588381A (en) 2012-05-25
US20160347811A1 (en) 2016-12-01
HUE030652T4 (en) 2017-09-28
PL2808340T3 (pl) 2017-02-28
AU2017225020A1 (en) 2017-09-28
KR20170110741A (ko) 2017-10-11
PT2268666E (pt) 2014-06-25
AU2017204258B2 (en) 2017-08-17
MX348622B (es) 2017-06-22
IL208538A (en) 2014-03-31
IL208538A0 (en) 2010-12-30
HK1146284A1 (en) 2011-05-20
US8951967B2 (en) 2015-02-10
HUS1700025I1 (hu) 2017-06-28
LTPA2017029I1 (lt) 2017-10-10
AU2017225020B2 (en) 2019-11-14
ES2629392T3 (es) 2017-08-09
NO2017025I1 (no) 2017-06-06
US9546204B2 (en) 2017-01-17
CY1115413T1 (el) 2017-01-04
BRPI0910461B8 (pt) 2021-05-25
PT2808340T (pt) 2016-11-21
AU2009237479A1 (en) 2009-10-22
EP3144318B1 (en) 2020-09-23
TWI488640B (zh) 2015-06-21
AU2017204259B2 (en) 2017-08-17
CA2725257A1 (en) 2009-10-22
AU2014203277B2 (en) 2017-04-06
BRPI0910461A8 (pt) 2018-10-16
MX2010011343A (es) 2011-01-20
HRP20170958T1 (hr) 2017-09-22
KR20190092608A (ko) 2019-08-07
SI3045471T1 (sl) 2017-07-31
HUS1700024I1 (hu) 2017-06-28
FR17C1020I2 (fr) 2020-04-10
EP2808340B1 (en) 2016-08-17
JP2017060476A (ja) 2017-03-30
SI2268666T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
HRP20161520T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
JP2018021037A5 (hr)
IL274602A (en) Pharmaceutical tablets containing altrombophage ulmin, methods for their preparation and use in the preparation of drugs for the treatment of thrombocytopenia
JP2012508904A5 (hr)
PH12013502192A1 (en) Antibodies against human angiopoietin 2
HRP20220500T1 (hr) Pripravci i postupci za glikoziliranje proteina
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
BR112014014025A2 (pt) prótese luminal e dispostivo de implante gastrointestinal
EP3336182A3 (en) Modified phosphatases
ATE541863T1 (de) Redispergierbare nanopartikel
PL2352386T3 (pl) Sposób wytwarzania związku kwasu n-masłowego w postaci mikrokapsułkowanej do spożycia przez zwierzęta lub ludzi
WO2008019850A3 (de) Vorrichtung zum bearbeiten und/oder handling von gegenständen
ZA201201222B (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases
JP2008531710A5 (hr)
WO2009153017A3 (de) Vorrichtung zur serienmässigen gefriertrocknung
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
CL2008000906A1 (es) Compuestos derivados de benzimidazol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por la actividad del receptor 2 cannabinoide.
WO2009024838A3 (en) Impression and model components
RS54214B1 (en) MIXTURE FOR USE IN THE TREATMENT OF INFERTILITY
HUP0700203A2 (en) Sustained release, core-shell structure precipitated citokine bionanocomposit, a process for producing the same and use thereof
HRP20201688T1 (hr) Rekombinantni fsh koji ukjlučuje alfa 2,3- i alfa 2,6-sialilaciju
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.
Sardelić Literary sources from the end of the 2nd to the end of the 6th century
Jergović et al. Treatment in the event of the non-conforming water for human consumption
Tamanti LE DICHIARAZIONI ANTICIPATE DI TRATTAMENTO (DAT).